Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 juin 2016 08h00 HE | Source: Zogenix, Inc.

Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome

EMERYVILLE, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders,...
31 mai 2016 08h00 HE | Source: Zogenix, Inc.

Zogenix to Participate in Jefferies 2016 Healthcare Conference

EMERYVILLE, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders,...
10 mai 2016 16h01 HE | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results

EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
05 mai 2016 08h00 HE | Source: Zogenix, Inc.

Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome

Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14th International Child Neurology Congress on the Use of Low-Dose Fenfluramine...
03 mai 2016 08h00 HE | Source: Zogenix, Inc.

Zogenix to Release First Quarter 2016 Financial Results and Host Conference Call and Webcast on May 10

EMERYVILLE, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
21 avr. 2016 08h00 HE | Source: Zogenix, Inc.

New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress

EMERYVILLE, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
10 mars 2016 16h00 HE | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results

EMERYVILLE, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
04 mars 2016 08h00 HE | Source: Zogenix, Inc.

Zogenix to Release Fourth Quarter and Full-Year 2015 Financial Results and Host Conference Call and Webcast on March 10

EMERYVILLE, Calif., March 04, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
03 févr. 2016 08h00 HE | Source: Zogenix, Inc.

Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference

EMERYVILLE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
19 janv. 2016 08h00 HE | Source: Zogenix, Inc.

Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome

EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...

Page précédente

Page suivante